Xiao-bo Zhong

University of Connecticut

H指数:37

被引数:4,629

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ESCRT-I complex enhances therapeutic efficacy of ASO drugs by regulating endosomal escape and glucose homeostasis

ESCRT-I复合物通过调控内体逃逸和葡萄糖稳态增强ASO药物的疗效

Molecular Therapy Nucleic Acids

IF6.1

2026-08-010

PRE

Liver transcriptomics reveals dysregulated hepatic absorption, distribution, metabolism, and excretion signatures in a mouse model of erythropoietic protoporphyria

肝脏转录组学揭示红细胞生成性原卟啉症小鼠模型中肝吸收、分布、代谢和排泄特征的失调

Drug Metabolism and Disposition

IF4

2026-08-010

PRE

Hnf1aos1 as a Metabolic Coordinator of Hepatic Lipid Homeostasis and Feedback Control

Hnf1aos1作为肝脂质稳态和反馈控制的代谢协调因子

Non-Coding RNA

IF3

2026-05-010

OAAI

Glucose-Dependent Effects on Intracellular Trafficking and Disposition of ASO Drugs

葡萄糖依赖性对ASO药物细胞内转运和分布的影响

Journal of Pharmacology and Experimental Therapeutics

IF3.8

2026-05-010

PRE

Cholesterol-dependent control of endosomal escape regulates intracellular trafficking of small interfering RNA therapeutics and interactions with small molecule drugs

the journal of pharmacology and experimental therapeutics

IF0

2026-01-210

PRE

The Non-Coding RNA Journal Club: Highlights on Recent Papers—14

非编码RNA期刊俱乐部：近期论文亮点—14

Non-Coding RNA 2025, Vol. 11, Page 75

IF0

2025-10-310

OAAI

Unraveling the Regulatory Impact of LncRNA Hnf1aos1 on Hepatic Homeostasis in Mice

解析LncRNA Hnf1aos1对小鼠肝脏稳态的调控影响

non coding rna research

IF0

2025-08-090

OAAI

Visualization of CYP3A4 expression at both mRNA and protein levels simultaneously at single cell resolution in various conditions using RNAscope combined with immunofluorescence

使用RNAscope结合免疫荧光技术，在不同条件下同时以单细胞分辨率在mRNA和蛋白水平可视化CYP3A4的表达。

Drug Metabolism and Disposition

IF4

2025-07-280

PRE

Intracellular fatty acid levels differentially impact target silencing by FDA-approved siRNA drugs

细胞内脂肪酸水平差异性地影响FDA批准的siRNA药物对靶点的沉默

Biochemical Pharmacology

IF5.6

2025-07-270

PRE

The ASO drug olezarsen targets familial chylomicronemia syndrome

ASO药物olezarsen靶向家族性乳糜微粒血症综合征

Trends in Pharmacological Sciences

IF19.9

2025-06-050

PRE

Impact on efficacy of target reduction of two FDA-approved ASO drugs by intracellular glucose levels in in vitro cell models

MOLECULAR THERAPY NUCLEIC ACIDS

IF6.1

2025-03-010

OAAI

Distinct Functional Roles of HNF1A-AS1 Transcripts in Regulating Drug-metabolizing Enzymes

HNF1A-AS1转录本在调控药物代谢酶方面的不同功能角色

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2025-03-010

PRE

Role of HNF4A-AS1/HNRNPC-mediated HNF4A ubiquitination protection against ritonavir-induced hepatotoxicity

MOLECULAR PHARMACOLOGY

IF3

2025-02-010

PRE

The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage

2024诺贝尔生理学或医学奖: microRNA成为中心舞台

non coding rna research

IF3

2024-12-123

OAAI

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs

BIODRUGS

IF6.9

2024-06-255

PRE

Identification and Functional Characterization of Alternative Transcripts of LncRNA HNF1A-AS1 and Their Impacts on Cell Growth, Differentiation, Liver Diseases, and in Response to Drug Induction

non coding rna research

IF3

2024-04-213

OAAI

The long noncoding RNA HNF1A-AS1 with dual functions in the regulation of cytochrome P450 3A4

BIOCHEMICAL PHARMACOLOGY

IF5.6

2024-02-015

PRE

Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin

PHARMACOLOGICAL REVIEWS

IF17.3

2024-01-018

ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis

TRENDS IN PHARMACOLOGICAL SCIENCES

IF19.9

2023-12-017

PRE

A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics

ADVANCED DRUG DELIVERY REVIEWS

IF17.6

2023-10-0120

OAAI

Xiao-bo Zhong

个人简介

教育背景

工作经历

荣誉奖项

研究方向